English flagItalian flagKorean flagChinese (Simplified) flagPortuguese flagGerman flagFrench flagSpanish flagJapanese flagArabic flagRussian flagGreek flagDutch flagBulgarian flagHindi flagSwedish flagIndonesian flag

Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher Disease

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company’s enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease. This is the third marketing application for velaglucerase alfa that has been submitted, with previous submissions in the United States and Canada.

source : www.medicalnewstoday.com

Related News:


Details :
Submited at Wednesday, November 25th, 2009 at 1:00 pm on Endocrinology by jessica
Comment RSS 2.0 - leave a comment - trackback
Leave Comment Here...
Name (required)
Email (required)
Website / Url